Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open-label, Multi-center, Phase 3 Study to Evaluate the Immunogenicity and Safety of an Inactivated EV71 Enterovirus Vaccine (Envacgen®) in Children Aged 6 to <10 Years Compared to Children Aged 2 to <6 Years

NCT07178522 is registered in ClinicalTrials.gov with Medigen Vaccine Biologics Corp. as lead sponsor.

NCT NCT07178522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07178522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open-label, Multi-center, Phase 3 Study to Evaluate the Immunogenicity and Safety of an Inactivated EV71 Enterovirus Vaccine (Envacgen®) in Children Aged 6 to <10 Years Compared to Children Aged 2 to <6 Years
Lead sponsor
Medigen Vaccine Biologics Corp.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 25, 2025
Completion date
October 31, 2026
Enrollment
379 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

enterovirus 71 inactivated vaccine